key: cord-0931053-if457lwh
authors: Hoertel, Nicolas; Sánchez-Rico, Marina; Herrera-Morueco, Juan José; de la Muela, Pedro; Gulbins, Erich; Kornhuber, Johannes; Carpinteiro, Alexander; Becker, Katrin Anne; Cougoule, Céline; Limosin, Frédéric
title: Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: Results from 49,089 COVID-19 inpatients
date: 2021-11-26
journal: Mol Psychiatry
DOI: 10.1038/s41380-021-01393-7
sha: 3a8144f85b408bcc0cbf2a5589c08cbac6a2e179
doc_id: 931053
cord_uid: if457lwh

nan

diagnosis codes in which each comorbidity category is dichotomous, i.e. either present or not present. It was initially designed to predict hospital resource use and in-hospital mortality [8] . Second, to assess the potential effect of unmeasured confounding, we computed E-values [9] . The E-value quantifies the minimum strength of association that an unmeasured confounder must have with both the predictor and the outcome, while simultaneously considering the measured covariates, to negate the observed association [9] . The lowest possible E-value is 1 (i.e., no unmeasured confounding is needed to explain away the observed association).

Of 49,089 adult patients hospitalized for COVID-19, 3768 (7.7%) had an ICD-10 diagnosis of psychiatric disorder. Distributions of age, sex, hospital, period of hospitalization, current hospitalization status, and medical comorbidities according to a psychiatric disorder diagnosis, and their associations with mortality are detailed in Supplementary Tables 1-3 and Supplementary Fig. 2 . During a median follow-up period of 45 days (SD = 122.1), death occurred in 1001 of 3768 (26.6%) patients with a psychiatric disorder diagnosis versus 3,780 of 45,321 (8.3%) in patients without this diagnosis (OR = 3.98; 95%CI = 3.67-4.31; p < 0.001). Similar to the results of Vai et al [1] , this association remained significant but was substantially reduced when adjusting for age and sex (AOR = 1.71; 95%CI = 1.57-1.86; p < 0.001; degrees of freedom (df) = 7). Additional adjustment for hospital, period of hospitalization, and current hospitalization did not alter the significance of the association (AOR = 1.35; 95%CI = 1.24-1.48; p < 0.001; df = 10). However, when further adjusting for the number of medical conditions, this association was significant and reversed (AOR = 0.87; 95%CI = 0.79-0.96; p = 0.005; df = 12) ( Fig. 1; Supplementary number of medical conditions, nor when considering the composite outcome of intubation or death instead of mortality (Fig. 1, Supplementary Tables 4 and 5 ). In the main fully-adjusted model, the E-value was 1.59, with a lower limit of the 95% confidence interval (95%CI) closest to the null point of 1.25, indicating that substantial unmeasured confounding would be required to "explain away" the negative association found between any psychiatric disorder and the outcome. Similarly, in the fully-adjusted model including the Elixhauser Comorbidity Index, the E-value was 1.46, with a lower limit of the 95%CI of 1.11.

Our study has several limitations. First, an inherent bias in observational studies is unmeasured confounding. To try to minimize the effects of confounding, we performed the analyses while adjusting for several known confounders and did an e-value analysis. However, data on several potential confounders, including baseline severity of SARS-CoV-2 infection, treatments that patients received, and certain sociodemographic characteristics, such as socioeconomic status, were not available for most patients included in these analyses. Second, there is a potential underreporting of psychiatric disorders and medical comorbidities in our sample in a context of overwhelmed hospital units during the peak incidences. Third, diagnoses of psychiatric disorders were based on ICD-10 diagnosis codes and not ascertained by psychiatrists. Finally, despite the multicenter design, our results may not be generalizable to outpatients and other countries.

Despite these limitations, our results suggest that among patients hospitalized for COVID-19, those with psychiatric disorders have increased risk of death, which could be explained by their greater number of medical conditions. In addition, by suggesting a possible negative association after adjusting for age, sex, comorbid medical disorders, hospital, period of hospitalization, and current hospitalization, our findings might help reconciliate findings from Vai et al. [1] . and recent in-vitro [10] , observational [5, 6] , and clinical ones [11, 12] , including the preliminary findings from the TOGETHER trial [13] , suggesting that certain antidepressants, such as fluvoxamine and fluoxetine, could be beneficial against COVID-19 [14] . Biological mechanisms that may contribute to this potential effect include functional inhibition of the acid sphingomyelinase/ceramide system [14, 15] , agonist effect for Sigma-1 receptors [16] , reduction in platelet aggregation, decreased mast cell degranulation, and interference with endolysosomal viral trafficking [16] .

Our findings support that individuals suffering from both psychiatric disorders and comorbid medical conditions should be vaccinated against COVID-19 and benefit from prevention and treatment of medical risk factors of severe COVID-19 as a priority. Future studies taking into account main medical risk factors of severe COVID-19, i.e. age and all medical comorbidities, will be important to determine whether the risk of COVID-19-related mortality is similar or different across psychiatric diagnoses and psychotropic medications prescribed. ]. *Two-sided p value is significant (p < 0.05). ***Two-sided p value is significant (p < 0.001). OR odds ratio, CI confidence interval, df degrees of freedom, GVIF generalized variance inflation factor.

Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. The Lancet Psychiatry

Takeuchi D Collaborative Psychiatric Epidemiology Surveys (CPES)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Sixty-Day Outcomes Among Patients Hospitalized With COVID-19

Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry

Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study

Epub ahead of print

Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: a multicenter retrospective observational study

Comorbidity measures for use with administrative data

Using the E-value to assess the potential effect of unmeasured confounding in observational studies

Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells

Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial

Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial

Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms

The acid sphingomyelinase/ceramide system in COVID-19

Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharm

We thank the EDS APHP Covid consortium integrating the APHP Health Data Warehouse team as well as all the APHP staff and volunteers who contributed to the implementation of the EDS-Covid database and operating solutions for this database. 

The authors declare no competing interests.

This observational study using routinely collected data received approval from the Institutional Review Board of the AP-HP clinical data warehouse (decision CSE-20-20_COVID19, IRB00011591, April 8th, 2020). AP-HP clinical Data Warehouse initiatives ensure patient information and consent regarding the different approved studies through a transparency portal in accordance with European Regulation on data protection and authorization n°1980120 from National Commission for Information Technology and Civil Liberties (CNIL).

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41380-021-01393-7.Correspondence and requests for materials should be addressed to Nicolas Hoertel.Reprints and permission information is available at http://www.nature.com/ reprintsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.